A variation in NOS1AP gene is associated with repaglinide efficacy on insulin resistance in type 2 diabetes of Chinese. - Wikidata - awgldk - TriplyDB

A variation in NOS1AP gene is associated with repaglinide efficacy on insulin resistance in type 2 diabetes of Chinese.

A variation in NOS1AP gene is associated with repaglinide efficacy on insulin resistance in type 2 diabetes of Chinese.

http://www.wikidata.org/entity/Q33814072

about

Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.Serum uric acid levels are associated with polymorphisms in the SLC2A9, SF1, and GCKR genes in a Chinese population Joint effects of diabetic-related genomic loci on the therapeutic efficacy of oral anti-diabetic drugs in Chinese type 2 diabetes patients.Positive association between rs10918859 of the NOS1AP gene and coronary heart disease in male Han Chinese.The pharmacogenetics of type 2 diabetes: a systematic review.Repaglinide: a review of its use in type 2 diabetes mellitus.Genetic advances of type 2 diabetes in Chinese populations.The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs.Mechanisms of NOS1AP action on NMDA receptor-nNOS signaling.Pharmacogenomics of glinides.Effects of NOS1AP rs12742393 polymorphism on repaglinide response in Chinese patients with type 2 diabetes mellitus.Neutrophil microparticle production and inflammasome activation by hyperglycemia due to cytoskeletal instability.Effects of KCNQ1 polymorphisms on the therapeutic efficacy of oral antidiabetic drugs in Chinese patients with type 2 diabetes.PPARD rs2016520 polymorphism affects repaglinide response in Chinese Han patients with type 2 diabetes mellitus.

P2860

Q30571118-DCA98EED-942B-4F8C-8A7F-A7620D0642F6 Q34451969-723F4E43-0C4A-4851-A2EC-299BE32F6D4A Q36694000-34EE4A47-97E9-4480-BDDD-3F3D6B1B9850 Q37519396-3FD4D31A-F424-4711-804C-8745CF77C1FB Q37597017-4DEB69BB-E660-461C-996B-31F545B2C683 Q37977979-782D0390-304F-4D88-B623-96D580901BFF Q38025234-F4802C12-5C41-47EA-B810-81B2B2383E3F Q38110432-254089C0-A128-4D12-9269-A7BFEF1FB2CA Q38249173-1246480B-5AF4-41ED-95ED-510A69882996 Q38307994-A88F8C4E-52CD-4042-9214-3A286EB99475 Q44748976-DC1BABE2-2C6F-4E60-BF31-9278DDA86248 Q46296309-A85D7CFC-501B-4571-B3C7-F0BEFFE64114 Q51380246-1140C4B1-F0D8-47F2-9D20-AB966762038F Q54188688-90F3F779-BC07-461E-A73D-F8E7A250F7BA

P2860

A variation in NOS1AP gene is associated with repaglinide efficacy on insulin resistance in type 2 diabetes of Chinese.

http://www.wikidata.org/entity/Q33814072

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A variation in NOS1AP gene is ...... in type 2 diabetes of Chinese.

@ast

A variation in NOS1AP gene is ...... in type 2 diabetes of Chinese.

@en

type

label

A variation in NOS1AP gene is ...... in type 2 diabetes of Chinese.

@ast

A variation in NOS1AP gene is ...... in type 2 diabetes of Chinese.

@en

prefLabel

A variation in NOS1AP gene is ...... in type 2 diabetes of Chinese.

@ast

A variation in NOS1AP gene is ...... in type 2 diabetes of Chinese.

@en

P1433

Q33814072-FFD64AEB-B40D-4A36-BF20-3FC9E18EADD7

P1476

Q33814072-9447DFC8-AC34-4699-A3FD-9E81B42E545F

P2093

Q33814072-0A456590-996B-4DE7-B90A-66F4D97B5EF6

Q33814072-26540807-5518-4DB5-94B6-B657C9DB7DF5

Q33814072-3F2522F0-A896-42A1-A6F5-1607A72807AA

Q33814072-AB06D488-1EF0-4EF8-B683-49C6EC7088C1

Q33814072-AE75A105-C144-4899-ABD4-FED188488C06

Q33814072-AE968E8B-DF99-4EF9-85FD-95683A064245

Q33814072-B90D51E5-D70B-4144-B2C3-659292E4E66C

Q33814072-C65C14B4-5ABF-48B2-A5D8-BB0D3CED300D

Q33814072-DE42A49E-C875-445B-81F2-9FB8CEC7DD44

Q33814072-FAF1EB04-8264-40BB-AD46-18101E2EAFE1

P2860

Q33814072-029EE898-E37F-4609-A8C8-CDC1BAD718EE

Q33814072-0EEB1BBA-057C-49CD-AA96-BA48C779263A

Q33814072-40584BA9-7D17-49A9-888E-35AC37389E13

Q33814072-45286B7D-3593-45A2-B163-4F263F33E8A0

Q33814072-4A980E52-18C9-47B6-98AD-3FFBBB0BFECC

Q33814072-515FCFCF-87CF-4FAD-9E1F-2CC05EC6AA7B

Q33814072-5972C93C-97DF-4392-B7F4-8824F3230814

Q33814072-5B744398-78F8-441D-B230-B7872FD095E2

Q33814072-618BDAC9-D868-46A8-AFDD-EC91027F8FF1

Q33814072-642DFECD-1F13-4F9D-AE7F-B5EF8731FC1F

P2888

Q33814072-83EB3CA9-6043-403D-8694-FF1BC5AA2F84

P304

Q33814072-C5CA9BFD-8F7E-47B4-B065-EEED222B3129

P31

Q33814072-41D12F5E-4067-4C33-A20F-F04A8D9B2CBB

P356

Q33814072-4D084708-7294-4210-B5DD-AD002653AA51

P433

Q33814072-BF45DE9A-0C0C-4EEC-B6A4-DA9CB6147822

P478

Q33814072-61C66C01-18E4-4ECF-9578-56A2421D0CF7

P577

Q33814072-A9A3C951-063D-49BB-A1AC-8214B269CCB0

P5875

Q33814072-CAF37217-6903-4E70-A2E1-A0B83FB29B69

P6179

Q33814072-41A34186-08DC-4FBC-B89B-0FE590903844

P698

Q33814072-4358B7DD-8743-4F7A-9A5B-EB8E257C27A6

P921

Q33814072-A1600131-C03D-40DA-A797-FEDBA82C6198

Q33814072-CB5D9E3F-7379-4E3D-A58B-B3D2A2199361

P932

Q33814072-6EDA8F58-38BF-4150-82E4-CB5D209FAB4D

P356

P1433

Acta Pharmacologica Sinica

P1476

A variation in NOS1AP gene is ...... in type 2 diabetes of Chinese.

@en

P2093

Cheng Hu

http://www.w3.org/2001/XMLSchema#string

Cong-rong Wang

http://www.w3.org/2001/XMLSchema#string

International Type 2 Diabetes 1q Consortium

http://www.w3.org/2001/XMLSchema#string

Jing-yi Lu

http://www.w3.org/2001/XMLSchema#string

Kun-san Xiang

http://www.w3.org/2001/XMLSchema#string

Rong Zhang

http://www.w3.org/2001/XMLSchema#string

Wei-hui Yu

http://www.w3.org/2001/XMLSchema#string

Wei-ping Jia

http://www.w3.org/2001/XMLSchema#string

Wen Qin

http://www.w3.org/2001/XMLSchema#string

Yu-qian Bao

http://www.w3.org/2001/XMLSchema#string

P2860

CAPON: a protein associated with neuronal nitric oxide synthase that regulates its interactions with PSD95

A note on exact tests of Hardy-Weinberg equilibrium

Insulin, nitric oxide and the sympathetic nervous system: at the crossroads of metabolic and cardiovascular regulation.

Endogenous nitric oxide synthesis: biological functions and pathophysiology.

Regulation of endothelial nitric oxide synthase by small RNA.

Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release

The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus.

NOS1AP variant associated with incidence of type 2 diabetes in calcium channel blocker users in the Atherosclerosis Risk in Communities (ARIC) study.

Nitric oxide release accounts for insulin's vascular effects in humans.

Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.

P2888

P304

450-454

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/APS.2010.25

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42372635

http://www.w3.org/2001/XMLSchema#string

P6179

1001138750

http://www.w3.org/2001/XMLSchema#string

P698

20305679

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

2860533

http://www.w3.org/2001/XMLSchema#string